A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC Meeting Abstract
| Authors: | Rudin, C. M.; Pietanza, M. C.; Spigel, D. R.; Bauer, T. M.; Glisson, B.; Robert, F.; Ready, N.; Morgensztern, D.; Kochendoerfer, M. D.; Patel, M.; Salgia, R.; Strickland, D. K.; Govindan, R.; Burris, H.; Dylla, S. J. |
| Abstract Title: | A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC |
| Meeting Title: | 16th World Conference on Lung Cancer (WCLC) |
| Keywords: | sclc; adc; tumor-initiating cell |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 10 |
| Issue: | 9 Suppl. 2 |
| Meeting Dates: | 2015 Sep 6-9 |
| Meeting Location: | Denver, CO |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S192 |
| End Page: | S193 |
| Language: | English |
| ACCESSION: | WOS:000370365100262 |
| PROVIDER: | wos |
| PUBMED: | 26710300 |
| DOI: | 10.1016/S1556-0864(16)30010-7 |
| Notes: | Meeting Abstract: ORAL10.01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
